Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lyme disease: pathogenesis and vaccine development.

M M Simon1, Y Bauer, W Zhong

  • 1Max-Planck-Institut für Immunbiologie, Freiburg, Germany. simon@immunbio.mpg.de

Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology
|February 1, 2000
PubMed
Summary

A novel Lyme disease vaccine targeting outer surface lipoprotein A (OspA) shows promise by eliminating Borrelia burgdorferi from ticks. However, European strains necessitate a more complex vaccine for comprehensive protection against Lyme disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pfeifer-Weber-Christian syndrome associated with Kikuchi syndrome in infliximab therapy: development of necrotizing allergic vasculitis].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2007
Same author

[Purely natural: phototoxic dermatitis].

MMW Fortschritte der Medizin·2007
Same author

Outbreak of tropical rat mite (Ornithonyssus bacoti) dermatitis in a home for disabled persons.

Dermatology (Basel, Switzerland)·2007
Same author

Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial.

The British journal of dermatology·2007
Same author

[Burning pain on one side of the body and blisters filled with clear fluid. Tentative diagnosis: shingles].

MMW Fortschritte der Medizin·2006
Same author

Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus.

The British journal of dermatology·2006

Area of Science:

  • Immunology
  • Microbiology
  • Vaccinology

Background:

  • Recent research has advanced understanding of Borrelia burgdorferi (B. burgdorferi) antigenic structures and genetic diversity.
  • Mechanisms of host-parasite interactions and immune responses in Lyme disease are increasingly understood.

Purpose of the Study:

  • To evaluate the efficacy of an outer surface lipoprotein A (OspA)-based vaccine for Lyme disease prevention.
  • To address the need for a more complex vaccine formula for European Borrelia burgdorferi (B. burgdorferi) strains.

Main Methods:

  • Clinical trial involving approximately 10,000 subjects in the USA to test an OspA vaccine.
  • Analysis of antigenic and genotypic variability of Borrelia (B.) burgdorferi sensu lato isolates.

Related Experiment Videos

Main Results:

  • The OspA vaccine demonstrated protection by eliminating spirochaetes from the vector (tick).
  • The vaccine does not cure established Lyme disease as OspA is not expressed in the vertebrate host.
  • Significant heterogeneity of OspA molecules among European Borrelia (B.) burgdorferi isolates limits cross-protection.

Conclusions:

  • The OspA vaccine is effective in preventing Lyme disease infection by targeting the vector.
  • A monovalent OspA vaccine is insufficient for full protection in Europe due to strain heterogeneity.
  • Development of a multivalent or more complex vaccine is required for comprehensive Lyme disease prevention in Europe.